Nurix Therapeutics, Inc. last reported quarterly results on Oct 13, 2026, for Q3 FY2026 (the quarter ended Aug 31, 2026): revenue of $673.1 million (+8426.3% year over year) and diluted EPS of $4.73. It usually reports 39–59 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 27, 2027.
Results for Q4 FY2026, the quarter ending around Nov 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 28, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 39–59 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 13, 2026
43 days after quarter end
|
Q3 FY2026
ended Aug 31, 2026
|
673
+8426.3%
|
550
+736.2%
|
4.73
+559.2%
|
|
Jul 9, 2026
39 days after quarter end
|
Q2 FY2026
ended May 31, 2026
|
9
-79.5%
|
-90
-106.0%
|
-0.81
-55.8%
|
|
Apr 8, 2026
39 days after quarter end
|
Q1 FY2026
ended Feb 28, 2026
|
6
-66.1%
|
-87
-54.7%
|
-0.79
-17.9%
|
|
Jan 28, 2026
59 days after quarter end
|
Q4 FY2025
ended Nov 30, 2025
|
14
+2.2%
|
-78
-33.6%
|
-0.82
-10.1%
|
|
Oct 9, 2025
39 days after quarter end
|
Q3 FY2025
ended Aug 31, 2025
|
8
-37.3%
|
-86
-76.5%
|
-1.03
-53.7%
|
|
Jul 9, 2025
39 days after quarter end
|
Q2 FY2025
ended May 31, 2025
|
44
+264.3%
|
-43
+2.4%
|
-0.52
+26.8%
|
|
Apr 8, 2025
39 days after quarter end
|
Q1 FY2025
ended Feb 28, 2025
|
18
+11.3%
|
-56
-35.7%
|
-0.67
+11.8%
|
|
Jan 13, 2025
44 days after quarter end
|
Q4 FY2024
ended Nov 30, 2024
|
13
-12.4%
|
-59
-39.5%
|
-0.75
+2.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRIX (Nasdaq)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1549595
- Former names
- Nurix, Inc. (until Sep 18, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.